Andembry is the first prophylactic therapy for hereditary angioedema to target factor XIIa, inhibiting the top of the ...

With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene ...

Transformation in healthcare is ongoing and purpose-driven. It’s not a fleeting trend but a continuous process rooted in ...

Recently, Vermont senator Bernie Sanders and Maine senator Angus King introduced a bill to ban prescription drug advertising ...

Strategic actions by Supernus, Teva, Incyte, and BioNTech highlight growing momentum in advancing clinical-stage therapies ...

Starting July 7, 2025, the two highest doses of Zepbound will be available for a flat price of $499 per month, with shipments ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 ...

Viseven announced a new AI agent for its content creation platform eWizard. The new agent, called eVa, is able to communicate ...

RESVIA is now authorized for use in adults aged 18–59 years with an increased risk of respiratory syncytial virus-related ...

Keytruda marks the first perioperative anti-PD-1 treatment option for adults with PD-L1–positive resectable locally advanced ...

Approval of Zusduri was based on data from the Phase III ENVISION trial, which showed a 78% complete response at three months ...

The company focuses on specialty drugs and uses a combination of AI and human expertise to automate the process.